34 KB473 KB30 KB192920262010Čufer, TanjaOvčariček, TanjaSadikov, AleksanderTriller, Nadjaštevilka:10letnik:798 stranistr. 669-676ISSN:1318-0347COBISSID:27496409URN:URN:NBN:SI:doc-R26WENTCenSlovensko zdravniško društvoZdravniški vestnikCarcinoma, Non-Small-Cell LungC-Reactive ProteinC-reaktivna beljakovinaC-reaktivni proteinDrug TherapyhemoglobinHemoglobiniHemoglobinsKarcinom nemalocelični, pljučniLung NeoplasmsPljučne novotvorbepljučni rakpreživetjePreživetje, analizaprognozaRetrospective StudiesRetrospektivne študijeSurvival AnalysisPrognostic value of C-reactive protein and other classical factors in patients with advanced non-small cell lung carcinoma treated in routine clinical practice| Napovedna vrednost C-reaktivnega proteina in drugih dejavnikov pri bolnikih z napredovalim nedrobnoceličnim karcinomom pljuč zdravljenih rutinsko v klinični praksi| Napovedna vrednost C-reaktivnega proteina in drugih dejavnikov pri bolnikih z napredovalim nedrobnoceličnim karcinomom pljuč zdravljenih rutinsko v klinični praksi|Background: Prognostic factors may help the clinician in treatment decision making. The significance of C-reactive protein (CRP) as a negative prognostic factor has been shown in patients with different malignancies. However, only few studies have analyzed CRP as a prognostic factor in patients with advancednon-small cell lung cancer (NCLCS). The aim of this study was to evaluate the prognostic value of CRP and other prognostic factors in a group of unselected population of patients with advanced NCLSC treated with platinumbased chemotherapy. Methods: The retrospective study was conducted by reviewing 53 medical files of advanced NSCLC patients treated with platinum/gemcitabine at the University Clinic Golnik between May 2004 and November 2008. The median age of patients was 65 years, most of them were males (75 %), smokers or ex-smokers (81 %), with performance status 1 ( 64.2 %) and stage IV disease (83 %). The collected data included laboratory characteristics (Hb, platelet count, CRP, LDH) before chemotherapy, information on each individual patientćs therapy and outcome. The median number of chemotherapy cycles received was 4 (range, 1-6). Results: The medianprogression free survival (PFS) for the entire group was 4.8 months (range 0.20 months). Patients with elevated CRP levels (. 20 mg/l) had inferior PFS compared to those with low pretreatment CRP values (median PFS 8.4 vs 3.6 months, p=0.006). In Cox univariate regression analysis, CRP (p=0.016, HR=1.008, 95 %CI, 1.001.1.014), Hb (p=0.001, HR= 0.96, 95 %CI, 0.95.0.99), and comorbidity (p=0.051, HR=1.2, 95 %CI, 1.00 -1.45) were found to be significant prognostic factors; age, LDH, and platelet count on the other hand were not found to be significant prognostic factors. In multivariate analysis only CRP (p=0.048, HR=0.50, 95 %CI 0.26.0.99) and Hb (p=0.005, HR=0.97, 95 %CI, 0.95 -0.99) retained their independent prognostic value. (Abstract truncated at 2000 characters)TEXTznanstveno časopisjejournalsSlovenian National E-content AggregatorNational and University Library of SloveniaSlovensko zdravniško društvo